Small-Molecule Activators of Insulin-Degrading Enzyme Discovered through High-Throughput Compound Screening

DSpace/Manakin Repository

Small-Molecule Activators of Insulin-Degrading Enzyme Discovered through High-Throughput Compound Screening

Citable link to this page

. . . . . .

Title: Small-Molecule Activators of Insulin-Degrading Enzyme Discovered through High-Throughput Compound Screening
Author: Cabrol, Christelle; Huzarska, Malwina A.; Dinolfo, Christopher; Rodriguez, Maria C.; Reinstatler, Lael; Ni, Jake; Yeh, Li-An; Stein, Ross L.; Leissring, Malcolm A.; Cuny, Gregory Douglas; Selkoe, Dennis J.

Note: Order does not necessarily reflect citation order of authors.

Citation: Cabrol, Christelle, Malwina A. Huzarska, Christopher Dinolfo, Maria C. Rodriguez, Lael Reinstatler, Jake Ni, Li-An Yeh, et al. 2009. Small-Molecule Activators of Insulin-Degrading Enzyme Discovered through High-Throughput Compound Screening. PLoS ONE 4(4): e5274.
Full Text & Related Files:
Abstract: Background: Hypocatabolism of the amyloid β-protein (Aβ) by insulin-degrading enzyme (IDE) is implicated in the pathogenesis of Alzheimer disease (AD), making pharmacological activation of IDE an attractive therapeutic strategy. However, it has not been established whether the proteolytic activity of IDE can be enhanced by drug-like compounds. Methodology/Principal Findings: Based on the finding that ATP and other nucleotide polyphosphates modulate IDE activity at physiological concentrations, we conducted parallel high-throughput screening campaigns in the absence or presence of ATP and identified two compounds—designated Ia1 and Ia2—that significantly stimulate IDE proteolytic activity. Both compounds were found to interfere with the crosslinking of a photoaffinity ATP analogue to IDE, suggesting that they interact with a bona fide ATP-binding domain within IDE. Unexpectedly, we observed highly synergistic activation effects when the activity of Ia1 or Ia2 was tested in the presence of ATP, a finding that has implications for the mechanisms underlying ATP-mediated activation of IDE. Notably, Ia1 and Ia2 activated the degradation of Aβ by ∼700% and ∼400%, respectively, albeit only when Aβ was presented in a mixture also containing shorter substrates. Conclusions/Significance: This study describes the first examples of synthetic small-molecule activators of IDE, showing that pharmacological activation of this important protease with drug-like compounds is achievable. These novel activators help to establish the putative ATP-binding domain as a key modulator of IDE proteolytic activity and offer new insights into the modulatory action of ATP. Several larger lessons abstracted from this screen will help inform the design of future screening campaigns and facilitate the eventual development of IDE activators with therapeutic utility.
Published Version: doi:10.1371/journal.pone.0005274
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668070/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4872636

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters